First Russian volunteers inoculated with China's COVID-19 vaccine

On Monday, Russian pharmaceutical company Petrovax launched phase 3 clinical trials of Chinese COVID-19 vaccine candidate, Canci Biologics 5-nCoV, on first group of Russian volunteers in Moscow. Back in March, 5-nCOV was first vaccine to undergo clinical trials on humans in China, and phases 1 and 2 were conducted domestically.

Last month,  Russian company first shared with Sputnik its plans to carry out late-st clinical trials of Chinese vaccine candidate. In a statement obtained by Sputnik, company said, "Petrovax, CanSi Biologics Inc. and contract research organization OCT Clinical have launched vaccinations of first volunteers in Moscow treatment centers."

According to company, first volunteers are doing well.

"ne of m showed any undesirable effects. According to clinical regulations, study participants will be under direct supervision during first 28 days after vaccination and will have to undergo four interim face-to-face examinations," Petrovax underlined.

During trials,  vaccinated participants will develop a humoral and cellular immune response to COVID-19, company forecasted. Petrovax said it would continue to recruit volunteers. Over 3,000 applications were received so far.

Once Chinese vaccine is registered in Russia, Petrovax will be able to produce it at its facilities in Moscow Region.

RE: AstraZeneca's COVID-19 vaccine trials still on hold in US over safety concerns

Earlier, China even iculated its medical workers with one of four vaccines being tested in country, as per local media reports. medical workers were given vaccine under emergency use programme launched in July. Wu, during interview, also said that she took vaccine herself and so far hasn't experienced any verse effects from it. Wu, who is an official with China's Centre for Disease Control and Prevention (CDC), did t specify which vaccine she took.

RE: We'll share data: Russia's Sputnik V Covid vaccine scientists respond to published doubts

Vaccine development across globe

Meanwhile, re are currently more than 110 COVID-19 vaccines being developed across world, which are in various sts of development. According to World Health Organisation (WHO), most vanced candidate among se was AstraZeneca's AZD1222, which it was developing in partnership with Oxford University. vaccine, however, suffered a set back last week after makers h to stop trials because a volunteer fell ill. trials have resumed again with a hope that it will be rey by end of 2020 or by January next year. 

RE: Three vaccine candidates in different sts of clinical trial: Vardhan

RE: Despite urgency, pharma companies committed to science first policy on COVID-19 vaccine: Industry body

(With Inputs from ANI)